INTERVENTION 1:	Intervention	0
Arm I	Intervention	1
Patients receive vaccination comprising p53-infected autologous dendritic cells subcutaneously (SC) 1 week after completion of doxorubicin and cyclophosphamide, 1 week after completion of paclitaxel (or after surgery for patients with stage III disease), and at 6 and 12 weeks after completion of radiotherapy (for a total of 4 vaccinations).	Intervention	2
vaccination	VO:0000002	17-28
vaccination	VO:0000002	328-339
week	UO:0000034	102-106
week	UO:0000034	163-167
week	UO:0000034	271-275
doxorubicin	CHEBI:28748,BAO:0000639	127-138
cyclophosphamide	CHEBI:4026	143-159
paclitaxel	CHEBI:45863	188-198
surgery	OAE:0000067	209-216
disease	DOID:4,OGMS:0000031	245-252
radiotherapy	OAE:0000235	297-309
autologous dendritic cell-adenovirus p53 vaccine: Given subcutaneously on one of two schedules	Intervention	3
vaccine	VO:0000001	41-48
INTERVENTION 2:	Intervention	4
Arm II	Intervention	5
Patients receive vaccination comprising p53-infected autologous dendritic cells SC at 6, 8, 10, and 12 weeks after completion of radiotherapy.	Intervention	6
vaccination	VO:0000002	17-28
radiotherapy	OAE:0000235	129-141
autologous dendritic cell-adenovirus p53 vaccine: Given subcutaneously on one of two schedules	Intervention	7
vaccine	VO:0000001	41-48
DISEASE CHARACTERISTICS:	Eligibility	0
disease	DOID:4,OGMS:0000031	0-7
Histologically confirmed invasive breast cancer meeting the following criteria:	Eligibility	1
breast cancer	DOID:1612	34-47
Clinically locally advanced disease (stage III) with a primary tumor at least 4 cm by mammogram, ultrasound, or palpation AND/OR palpable axillary nodes larger than 1 cm	Eligibility	2
disease	DOID:4,OGMS:0000031	28-35
Planned neoadjuvant chemotherapy	Eligibility	3
p53-overexpressing tumor by immunohistochemistry	Eligibility	4
immunohistochemistry	BAO:0000415	28-48
Delayed-type hypersensitivity to at least 1 of 3 standard antigens	Eligibility	5
hypersensitivity	GO:0002524,DOID:1205	13-29
Hormone receptor status:	Eligibility	6
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
Not specified	Eligibility	7
PATIENT CHARACTERISTICS:	Eligibility	8
patient	HADO:0000008,OAE:0001817	0-7
Age	Eligibility	9
age	PATO:0000011	0-3
19 and over	Eligibility	10
Sex	Eligibility	11
Female	Eligibility	12
female	PATO:0000383	0-6
Menopausal status	Eligibility	13
Not specified	Eligibility	14
Performance status	Eligibility	15
ECOG 0-1	Eligibility	16
Life expectancy	Eligibility	17
Not specified	Eligibility	18
Hematopoietic	Eligibility	19
WBC > 4,000/mm^3	Eligibility	20
Platelet count > 100,000/mm^3	Eligibility	21
platelet count	CMO:0000029	0-14
Hepatic	Eligibility	22
Bilirubin < 2 times upper limit of normal (ULN)	Eligibility	23
Hepatitis B surface antigen negative	Eligibility	24
hepatitis b	DOID:2043	0-11
antigen	CHEBI:59132	20-27
Hepatitis C antibody negative	Eligibility	25
hepatitis c	DOID:1883	0-11
antibody	GO:0042571,BAO:0000502	12-20
Renal	Eligibility	26
Creatinine < 2 times ULN	Eligibility	27
creatinine	CHEBI:16737	0-10
Immunologic	Eligibility	28
HIV negative	Eligibility	29
No prior or concurrent autoimmune disorder	Eligibility	30
disorder	OGMS:0000045	34-42
Other	Eligibility	31
Not pregnant or nursing	Eligibility	32
Negative pregnancy test	Eligibility	33
Fertile patients must use effective contraception during and for at least 6 months after study participation	Eligibility	34
No other concurrent illness that would preclude study participation	Eligibility	35
PRIOR CONCURRENT THERAPY:	Eligibility	36
Biologic therapy	Eligibility	37
Not specified	Eligibility	38
Chemotherapy	Eligibility	39
See Disease Characteristics	Eligibility	40
disease	DOID:4,OGMS:0000031	4-11
No prior chemotherapy	Eligibility	41
Endocrine therapy	Eligibility	42
Not specified	Eligibility	43
Radiotherapy	Eligibility	44
radiotherapy	OAE:0000235	0-12
Not specified	Eligibility	45
Surgery	Eligibility	46
surgery	OAE:0000067	0-7
See Disease Characteristics	Eligibility	47
disease	DOID:4,OGMS:0000031	4-11
Other	Eligibility	48
No concurrent participation in another therapeutic clinical trial	Eligibility	49
Outcome Measurement:	Results	0
Number of Participants Who Experienced Toxicity to the Vaccine	Results	1
vaccine	VO:0000001	55-62
This outcome measure looks at the safety of the vaccine by documenting the number of grade 2, 3, or toxicities experienced by participants related to the vaccine.	Results	2
vaccine	VO:0000001	48-55
vaccine	VO:0000001	154-161
Time frame: 1 week after each vaccine dose.	Results	3
time	PATO:0000165	0-4
week	UO:0000034	14-18
vaccine	VO:0000001	30-37
Results 1:	Results	4
Arm/Group Title: Arm I	Results	5
Arm/Group Description: Patients receive vaccination comprising p53-infected autologous dendritic cells subcutaneously (SC) 1 week after completion of doxorubicin and cyclophosphamide, 1 week after completion of paclitaxel (or after surgery for patients with stage III disease), and at 6 and 12 weeks after completion of radiotherapy (for a total of 4 vaccinations).	Results	6
vaccination	VO:0000002	40-51
vaccination	VO:0000002	351-362
week	UO:0000034	125-129
week	UO:0000034	186-190
week	UO:0000034	294-298
doxorubicin	CHEBI:28748,BAO:0000639	150-161
cyclophosphamide	CHEBI:4026	166-182
paclitaxel	CHEBI:45863	211-221
surgery	OAE:0000067	232-239
disease	DOID:4,OGMS:0000031	268-275
radiotherapy	OAE:0000235	320-332
autologous dendritic cell-adenovirus p53 vaccine: Given subcutaneously on one of two schedules	Results	7
vaccine	VO:0000001	41-48
Overall Number of Participants Analyzed: 11	Results	8
Measure Type: Count of Participants	Results	9
Unit of Measure: Participants  0   0.0%	Results	10
Results 2:	Results	11
Arm/Group Title: Arm II	Results	12
Arm/Group Description: Patients receive vaccination comprising p53-infected autologous dendritic cells SC at 6, 8, 10, and 12 weeks after completion of radiotherapy.	Results	13
vaccination	VO:0000002	40-51
radiotherapy	OAE:0000235	152-164
autologous dendritic cell-adenovirus p53 vaccine: Given subcutaneously on one of two schedules	Results	14
vaccine	VO:0000001	41-48
Overall Number of Participants Analyzed: 12	Results	15
Measure Type: Count of Participants	Results	16
Unit of Measure: Participants  0   0.0%	Results	17
Adverse Events 1:	Adverse Events	0
Total: 5/11 (45.45%)	Adverse Events	1
Nausea 1/11 (9.09%)	Adverse Events	2
nausea	HP:0002018	0-6
Vomiting 1/11 (9.09%)	Adverse Events	3
vomiting	HP:0002013	0-8
Fever 1/11 (9.09%)	Adverse Events	4
fever	HP:0001945	0-5
skin infection  [1]1/11 (9.09%)	Adverse Events	5
Hip fracture 0/11 (0.00%)	Adverse Events	6
hip	UBERON:0001464	0-3
Confusion 1/11 (9.09%)	Adverse Events	7
confusion	HP:0001289	0-9
Adverse Events 2:	Adverse Events	8
Total: 1/12 (8.33%)	Adverse Events	9
Nausea 0/12 (0.00%)	Adverse Events	10
nausea	HP:0002018	0-6
Vomiting 0/12 (0.00%)	Adverse Events	11
vomiting	HP:0002013	0-8
Fever 0/12 (0.00%)	Adverse Events	12
fever	HP:0001945	0-5
skin infection  [1]0/12 (0.00%)	Adverse Events	13
Hip fracture 1/12 (8.33%)	Adverse Events	14
hip	UBERON:0001464	0-3
Confusion 0/12 (0.00%)	Adverse Events	15
confusion	HP:0001289	0-9
